Targeted binding agents directed to uPAR and uses thereof
AssigneeMedImmune, LLC
InventorsQing Zhou, Stephen Charles Emery, Paul Elvin
Life of this patent
Estimating the term…
Abstract
Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
Claims18
An isolated antibody, or binding fragment thereof, that specifically binds to urokinase-type plasminogen activator receptor (uPAR) and inhibits binding of urokinase-type plasminogen activator (uPA) to urokinase-type plasminogen activator receptor (uPAR), wherein said antibody is a monoclonal antibody having the amino acid sequence of the antibody produced by the hybridoma deposited at ATCC under Accession Number PTA-7475.
An isolated antibody, or binding fragment thereof, that specifically binds to uPAR, wherein said antibody comprises a heavy chain polypeptide comprising the sequence of SEQ ID NO.:
- 26 or SEQ ID NO:
- 26 comprising any one of the combinations of residues indicated by each row of Table 15, and a light chain polypeptide comprising the sequence of SEQ ID NO:
- 28, or SEQ ID NO:
- 28 comprising any one of the combinations of residues of SEQ ID NO:
- 28 indicated by each row of Table 14.
An isolated antibody, or binding fragment thereof, that specifically binds to urokinase-type plasminogen activator receptor (uPAR), wherein the antibody comprises:
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of TNYMN (SEQ ID NO:
- 94);
- a heavy chain complementarity determining region 2 (CDR2) having the amino acid sequence of IIYTGGSTSYADSVKG (SEQ ID NO:
- 95);
- a heavy chain complementarity determining region 3 (CDR3) having the amino acid sequence of EIAVAGYYGMDV (SEQ ID NO:
- 96);
- a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of RASQGIRNDLG (SEQ ID NO:
- 103);
- a light chain complementarity determining region 2 (CDR2) having the amino acid sequence of AASSLQS (SEQ ID NO:
- 104);
- and
- a light chain complementarity determining region 3 (CDR3) having the amino acid sequence of LQHNSYPLT (SEQ ID NO:
- 105).
Dependencies are inferred from the claim text.